Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer

BACKGROUND: Chemoimmunotherapy is a standard treatment for triple-negative breast cancer (TNBC), however, the impacts of different chemotherapies on T-cell populations, which could correlate with clinical activity, are not known. Quantifying T-cell populations with flow cytometry and T-cell receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Chun, Brie, Pucilowska, Joanna, Chang, ShuChing, Kim, Isaac, Nikitin, Benjamin, Koguchi, Yoshinobu, Redmond, William L, Bernard, Brady, Rajamanickam, Venkatesh, Polaske, Nathan, Fields, Paul A, Conrad, Valerie, Schmidt, Mark, Urba, Walter J, Conlin, Alison K, McArthur, Heather L, Page, David B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796261/
https://www.ncbi.nlm.nih.gov/pubmed/35086949
http://dx.doi.org/10.1136/jitc-2021-004033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796261/
https://www.ncbi.nlm.nih.gov/pubmed/35086949
http://dx.doi.org/10.1136/jitc-2021-004033

Ejemplares similares